ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Winter Conference & Expo
November 15–18, 2026
Phoenix, AZ|Arizona Grand Resort & Spa
Latest Magazine Issues
Sep 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
October 2026
Nuclear Technology
Fusion Science and Technology
Latest News
Westinghouse, Nordion, and PSEG team up to produce Co‑60 in the United States
This past January, Westinghouse Electric Company, Nordion, and PSEG Nuclear formalized agreements to implement newly developed cobalt-60 production technology at Units 1 and 2 of PSEG’s Salem nuclear power plant in New Jersey, with the Co-60 to be supplied to Nordion. Through an ongoing joint initiative, the companies aim to harness U.S. pressurized water reactors to produce a key medical isotope and build the first commercial-scale Co-60 production platform in the United States.
W. S. Kiger III, S. Sakamoto, O. K. Harling
Nuclear Science and Engineering | Volume 131 | Number 1 | January 1999 | Pages 1-22
Technical Paper | doi.org/10.13182/NSE99-A2015
Articles are hosted by Taylor and Francis Online.
To meet the needs for neutron capture therapy (NCT) irradiations, a high-intensity, high-quality fission converter-based epithermal neutron beam has been designed for the MITR-II research reactor. This epithermal neutron beam, capable of delivering treatments in a few minutes with negligible background contamination from fast neutrons and photons, will be installed in the present thermal column and hohlraum of the 5-MW MITR-II research reactor. Spent or fresh MITR-II fuel elements will be used to fuel the converter. With a fission converter power of ~80 kW using spent fuel, epithermal fluxes (1 eV < E < 10 keV) in excess of 1010 n/cm2s are achievable at the target position with negligible photon and fast neutron contamination, i.e., <2 × 10-11 cGycm2/n. With the currently available 10B delivery compound boronophenylalanine-fructose, average therapeutic ratios of ~5 can be achieved using this beam for brain irradiations with deep effective penetration (~9.5 cm) and high dose rates of up to 400 to 600 RBE cGy/min. If NCT becomes an accepted therapy, fission converter-based beams constructed at existing reactors could meet a large fraction of the projected requirements for intense, low-background epithermal neutron beams at a relatively low cost. The results of an extensive set of neutronic design studies investigating all components of the beam are presented. These detailed studies can be useful as guidance for others who may wish to use the fission converter approach to develop epithermal beams for NCT.